The UVA Cancer Center seeks adults ages 18 and over with urothelial (bladder) cancer for a clinical trial. The purpose of this study is to evaluate an investigative immunotherapy drug (derazantinib) alone or in combination with another immunotherapy drug (atezolizumab) in patients with urothelial cancer. Disease response and good and bad effects of the drug will be studied as part of this study. Study specific tests will be provided at no cost to you.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04045613
Compensation: $85 per visit. Reimbursement: Up to $175 for hotel stay.